A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2016
At a glance
- Drugs Bexarotene (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Therapeutic Use
- Acronyms BEAT-AD
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2015 Status changed from active, no longer recruiting to completed.
- 04 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record..